Shanghai MicroPort CardioFlow Medtech Co., Ltd.

Clinical trials sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd., explained in plain language.

Now part of MicroPort CardioFlow Medtech Corporation 2160 HKEX

A medical device company developing transcatheter heart valve products, a subsidiary of MicroPort Scientific.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New heart valve study aims to improve life for High-Risk patients Results expected Jun 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

Less invasive heart valve fix could rival Open-Heart surgery for tough cases

Disease control By invitation only

This study compares two ways to replace a narrowed heart valve in people with a bicuspid aortic valve (a common birth defect). One method is transcatheter aortic valve replacement (TAVR), a less invasive procedure using a tube inserted through a blood vessel. The other is traditi…

Sponsor: Shanghai MicroPort CardioFlow Medtech Co., Ltd. • Aim: Disease control

Last updated Jun 26, 2026 18:14 UTC

Shanghai MicroPort CardioFlow Medtech Co., Ltd.

Upcoming readouts

Less invasive heart valve fix could rival Open-Heart surgery for tough cases